Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis.
about
The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysisAdvances in the use of biologic agents for the treatment of systemic vasculitisPolymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial.Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.The utility of tumour necrosis factor blockade in orphan diseases.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Biologic agents in systemic vasculitis.Pharmacotherapy of vasculitis.Tumor necrosis factor biologics beyond psoriasis in dermatology.New indications for biological therapies.Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.Unmet Needs in the Pathogenesis and Treatment of Vasculitides.
P2860
Q26853258-1537A905-568B-4A26-B297-052C000D5678Q34065598-BB5CF128-CFE1-42D5-907C-2C7A8F06FB98Q34205665-AF73DF43-5C3C-4876-B30D-B658420E67F1Q34346251-29242FF2-ED80-4704-B2E4-C7C65308844FQ35579352-FA49A048-8956-4DB3-AF3B-DD7585E7FCC2Q35579517-BE806F10-C0C2-4E4F-B5BB-2E73602E02A1Q35638252-CAEAEA46-7A70-4E14-A70A-ED1CA57DCF94Q35915996-07ECDED0-4E92-4466-A563-B4DCAE0A1CCBQ36171750-70A62C27-985F-449A-8886-965CFDCDF2A9Q36934322-43EA6C36-21AB-4F9A-A8A4-C8CDDE761754Q37483910-1B0C0A4D-DD45-42A4-979D-7EF27CE2AB07Q37886194-0C41842D-37A8-4F64-BCCC-D0735B92D6CDQ37947157-0A92B436-9805-4C82-B030-C505814E3FCDQ39100312-A8EF9513-B147-4F56-BD00-39D4FE6F3720Q48592090-5C2DF3F6-9C9B-4830-8090-7962D8DD9AE4
P2860
Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Experience with infliximab (an ...... rapy for giant cell arteritis.
@en
Experience with infliximab
@nl
type
label
Experience with infliximab (an ...... rapy for giant cell arteritis.
@en
Experience with infliximab
@nl
prefLabel
Experience with infliximab (an ...... rapy for giant cell arteritis.
@en
Experience with infliximab
@nl
P2093
P356
P1476
Experience with infliximab (an ...... rapy for giant cell arteritis.
@en
P2093
Andonopoulos AP
Daoussis D
Giannopoulos G
Meimaris N
P356
10.1136/ARD.62.11.1116
P407
P577
2003-11-01T00:00:00Z